CHMP recommends EU approval of Roche’s Susvimo for neovascular AMD
The CHMP has recommended the approval of Susvimo, a continuous delivery treatment for neovascular AMD, based on positive clinical trial data.
Company
Roche
Asset
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The CHMP's recommendation for Roche's Susvimo marks a significant advancement in the treatment of neovascular AMD, potentially reshaping market dynamics. This novel continuous delivery system could enhance patient adherence and reduce treatment burden, positioning Roche favorably against competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the final decision from the European Commission and any subsequent market uptake and competitive responses from other nAMD therapies.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.